The MAGOH antibody is a tool used to detect MAGOH, a core component of the exon junction complex (EJC), which plays critical roles in mRNA splicing, export, surveillance, and translation. MAGOH, along with its binding partner Y14 (RBM8A), forms a heterodimer that anchors the EJC to spliced mRNAs. This complex influences mRNA stability, localization, and nonsense-mediated decay (NMD), a quality-control mechanism for eliminating faulty transcripts. MAGOH is essential for embryogenesis and cell cycle regulation, with dysregulation linked to cancer progression and developmental disorders.
Research on MAGOH antibodies has grown due to MAGOH's oncogenic potential. Overexpression of MAGOH is observed in cancers like glioblastoma and colorectal cancer, where it promotes tumor growth, metastasis, and therapy resistance by modulating pathways such as Wnt/β-catenin and PI3K/AKT. Antibodies against MAGOH enable studies of its expression patterns, interactions, and functional roles in both normal and diseased states. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate MAGOH's localization and abundance in tissues or cell lines.
Additionally, MAGOH antibodies have diagnostic and therapeutic implications, as MAGOH may serve as a biomarker or target for cancers. Ongoing studies explore its utility in precision oncology and its interplay with microRNAs in disease mechanisms.